The phase 3 data sharpen the picture
(GSH)
To identify the sensor Cys residues of KEAP1 involved in direct cysteinylation by free Cys, we incubated the recombinant purified KEAP1 with free Cys and determined by mass spectrometry that Cys residues 77, 151, 226, 288, 319, 489, 583, and 613 were modified by cysteinylation in vitro (Fig
While these drugs can be essential for patients who require personalized treatments, they can also present potential risks
At the same time, whats crossing the line to patent infringement or false advertising? The argument from telehealth companies involved in similar cases is that this is an attack on digital health by the deep-pockets pharma industry that is prioritizing profit over patients, Ferrante noted